BioCryst Pharmaceuticals is facing a patent infringement lawsuit in 2024 concerning its hereditary angioedema (HAE) drug, Orladeyo (berotralstat) [1]. The lawsuit was filed by Dyax Corp., a subsidiary of Shire (now Takeda), which alleges that Orladeyo infringes on two of its patents [1][2]. These patents relate to the use of certain kinase inhibitors for treating HAE [2].
What are the specific patents involved in the Orladeyo lawsuit?
The patents at the center of the infringement claim are U.S. Patent Nos. 8,349,849 and 9,056,054, both held by Dyax Corp [2]. These patents cover methods of treating HAE using specific types of kinase inhibitors, which Dyax argues Orladeyo falls under [2].
Why is Dyax Corp suing BioCryst over Orladeyo?
Dyax Corp. alleges that BioCryst's commercialization and sale of Orladeyo infringe upon its patented methods for treating HAE [1]. The lawsuit claims that BioCryst is aware of these patents and has willfully infringed them, leading Dyax to seek damages and injunctive relief [1].
What is the history of HAE treatments and related patents?
Hereditary angioedema is a rare genetic disorder characterized by recurrent swelling episodes. Before the development of newer oral therapies, treatment options were limited and often involved intravenous or subcutaneous injections. Patents in this area typically cover specific drug compounds, formulations, or methods of use for treating the condition. Dyax Corp. has a history in HAE research and development, with its acquisition by Shire in 2016 bringing its patent portfolio into Takeda's possession [2].
What are the potential outcomes of this patent infringement lawsuit?
The lawsuit could result in various outcomes, including BioCryst being found to infringe the patents, leading to potential financial penalties, royalties, or an injunction that could restrict Orladeyo's sale or marketing [1]. Conversely, BioCryst may successfully defend against the claims, potentially invalidating the asserted patents or demonstrating non-infringement. The legal proceedings will determine the validity and scope of Dyax's patents in relation to Orladeyo.
How might this lawsuit affect Orladeyo's market availability and BioCryst's business?
If the court rules in favor of Dyax, it could significantly impact Orladeyo's market position and BioCryst's revenue streams. This could involve substantial financial damages or limitations on Orladeyo's commercialization. The uncertainty surrounding the lawsuit can also affect investor confidence and BioCryst's strategic planning for the drug [1].
What are BioCryst's options in response to the lawsuit?
BioCryst can contest the lawsuit by arguing that Orladeyo does not infringe the patents, that the patents are invalid, or that its product is used in a manner not covered by the patent claims [1]. The company may also pursue settlement negotiations with Dyax Corp. to resolve the dispute outside of court.
Sources:
[1] https://drugpatentwatch.com/blog/biocryst-pharmaceuticals-inc-vs-dyax-corp-et-al-patent-infringement-lawsuit-filed-2024/
[2] https://www.law360.com/articles/1780317/takeda-unit-sues-biocryst-over-hereditary-angioedema-drug-patents